Get Game-Changing Results with GLP-1 Medications Start your weight loss journey with Ocean Drive today!

The Ocean Drive Plastic Surgery GLP-1 weight loss telemedicine program is powered by the CareGLP™ platform by CareValidate Inc. CareGLP is a patient management platform that collaborates with physicians and practitioners like those at Ocean Drive, providing services through the SOC2 and HIPAA Compliant Care360 platform.

All medical services are provided by Ocean Drive Plastic Surgery Center. The information presented on this website should not be considered a substitute for professional medical advice, diagnosis, or treatment.

Ocean Drive Plastic Surgery Center is committed to your privacy. Only our medical team and prescribers have access to your medical data and order history. Please refer to our Privacy Policy for additional details.

An existing prescription is not required to participate in the Ocean Drive Plastic Surgery weight loss program. If you meet the criteria for treatment, you will be provided with a personal prescription.

The monthly cost for compounded Semaglutide starts at $350. This fee includes telehealth consultations with Dr. Durkin's team, a personalized weight loss plan, a monthly prescription for GLP-1 medication, shipping to your home, and email and phone support. Price varies by dose and medication prescribed.

Semaglutide should not be used if you or any family members have had medullary thyroid carcinoma (MTC), or if you have a condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It's important to contact your healthcare provider right away if you experience any symptoms such as a lump or swelling in your neck, hoarseness, difficulty in swallowing, or shortness of breath, as these may be indicators of thyroid cancer.

The effectiveness and safety of Semaglutide in combination with other weight loss products are yet to be confirmed. It is vital to share your full medical history with your healthcare provider. This includes informing them if you have had conditions like Type 1 or Type 2 diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression, or any history of suicidal thoughts or behaviors.

Following a thorough assessment by the Ocean Drive Plastic Surgery medical team and the issuance of your prescription, you will receive your first shipment, typically within 5 to 7 days. Our process ensures a consistent supply of medication will arrive each month for your continued progress.

Weight reduction varies from person to person. Patients commonly report losing 5% to 10% of their starting weight, with longer treatment times tending toward more weight loss. For instance, a 200-pound person can expect to lose in the range of 10 to 20 pounds.

Please refer to our educational videos on GLP1 Injection How-to for guidance on subcutaneous injection. If you encounter any issues or have questions, please consult your doctor through the CareGLP support platform.

When a drug faces shortages, compounders can prepare a compounded version of that drug if they meet certain requirements in the Federal Food, Drug, and Cosmetic (FD&C) Act. Pharmacies in the CareGLP network comply strictly with all the regulatory standards established by:

• State boards of pharmacy, which regulate all 503A pharmacies
• The FDA which has oversight for the safety of all active pharmaceutical ingredients
• The DEA that oversees the controlled substances sometimes used in compounded preparations
• The USP Convention that issues practice standards ensuring quality and safety of medications and food
• The USP General Chapter 795 provides guidelines for the prevention of contamination and potency variance, preparation process, beyond-use dates, and stability for non-sterile compounding

Pharmacies in the CareGLP network run quality assurance and quality control checks for every batch of compounded Semaglutide prescribed to patients.Some of these steps include but are not limited to:

• Reviewing and confirming the Active Pharmaceutical Ingredient (API) Certificate of Analysis for all Semaglutide base lots, which are received from FDA-registered manufacturers
• Storing the verified API frozen and sealed until use
• Compounding with the API under aseptic processes to produce specific lots (vials)
• Holding the vials of compounded Semaglutide in quarantine (representative samples are taken for testing)
• Using independent third-party laboratories to test the potency, sterility and endotoxicity of each lot of compounded Semaglutide (among other criteria)
• Reviewing the results of these tests and, if satisfactory, releasing the validated vials from quarantine for dispensing
• Assigning each compounded lot a unique lot number and BUD (Beyond Use Date), which is added to the container and is tracked electronically
• Scanning the lot information on the product at the time of dispensing, which ties a particular lot number to the patient's file